1 / 30

Lung Transplantation

Lung Transplantation. David J. Ross, M.D. Medical Director, Lung & Heart-Lung Transplant Program Director, Pulmonary Hypertension Program Associate Professor of Medicine U.C.L.A. School of Medicine dross@mednet.ucla.edu. J.D. Hardy (1963): 1 st Human Lung Transplant.

adriel
Télécharger la présentation

Lung Transplantation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Lung Transplantation David J. Ross, M.D. Medical Director, Lung & Heart-Lung Transplant Program Director, Pulmonary Hypertension Program Associate Professor of Medicine U.C.L.A. School of Medicine dross@mednet.ucla.edu

  2. J.D. Hardy (1963):1st Human Lung Transplant • 58 y.o. male patient • (L) mainstem bronchogenic CA & (R) severe COPD • (L) Single lung tx on June 11, 1963. • Immunosuppression: AZA, prednisone, Cobalt irradiation. • Survived 18 days J.D. Hardy, W.R. Webb, M.L. Dalton, et al. JAMA 1963; 186:1065

  3. New York City Marathon (1998) • 32 y.o. male patient s/p bilateral lung tx for cystic fibrosis. • Completes marathon in 7:08:50 Scand J Med & Science in Sports, 2000

  4. Organ Transplants 2001: UNOS UNOS Statistics 5/1/02

  5. UNOS “Waiting List” UNOS Statistics 5/1/02

  6. Unilateral Interstitial Fibrosis COPD Pulmonary Hypertension Bilateral, sequential Bronchiectasis Cystic Fibrosis COPD (young patients) Pulmonary Hypertension Eisenmenger’s Syndrome (correctable) Lung Transplantation

  7. ISHLT Registry Data:Single versus Bilateral P<0.05 Meyer DM, et al. J Heart-Lung Transplant 2002; 20(9):935-41.

  8. SLT vs BLT by Recipient Age Meyer DM, et al. J Heart-Lung Transplant 2002; 20(9):935-41

  9. Bilateral Sequential LT:“Clam Shell” Incision

  10. Single Lung Transplant: IPF

  11. Alpha-1 Anti-trypsin Deficiency: Single Lung Transplant

  12. Median Waiting Times • Introduction of “Expanded Donor Criteria Program” in Sept 1999. • 1995-8 cohort (n=68): 317 days • 9/99-present (n=25): 105 days

  13. 1-year Survival 8 12 • Development of “New Team” in July 1999. • Medicare/HCFA Certification • “Expanded Donor Criteria” Program • “Waiting Time” Issues in Southern Cal 15 (N) 13 10 18 25 12

  14. Median Total Hospital LOS • Median ICU LOS with “Expanded Donor” is 3  4 days. • Acceptable allograft function without prolonged intubation • Inhaled N.O. only for established reperfusion injury. • “Modified reperfusion” CTS protocol

  15. UCLA Lung Transplant Program: Patient Survival Actual Survival, 10/1/97-6/1/02; N=70

  16. Relative Risk of Death for LT versus Continued Waiting Disease 6 mos 12 mos • COPD (163) 0.55 0.32 SLT (92) 0.58 0.38 DLT/HLT (35) 0.54 0.29 • C.F. (174) 0.21 0.15 • Eisenmenger (76) 1.26 0.85 • Bronchiectasis (51) 0.58 0.58 • IPF (100) 0.65 0.46 SLT (63) 0.71 0.54 DLT/HLT (47) 0.57 0.36 • PAH (68) 0.37 0.34 Charman SC, et al. J Heart and Lung Transplant 2002; 21(2):226-32.

  17. Pulmonary Arterial Hypertension in IPF Novel therapies for a serious complication

  18. Bosentan (Tracleer™) • Oral, dual ET-1 receptor antagonist • Class III/IV with either PPH or PSS (n=32). • 12 week placebo-controlled study. • Bosentan vs placebo: • 6-minute walk: +70 vs -6 meters • Cardiac index: +0.5 0.1 vs -0.50.1 L/min/m2 • mPAP: -1.6 1.2 vs +5.12.8 mm Hg • PVR: -22356 vs +19174 dynes/sec/cm-5 • RA: -1.30.9 vs +4.91.5 mm Hg[Mean SE] Channick R, et al. Lancet 2001; 358(9288):1119-23.

  19. Vascular Biology ET-1 AA COX PGI2 ETB ETB ETA BIG ET-1 ECE ET-1 CONTRACTION L-arginine NOS NO (–) cAMP K+/Ca2+ RELAXATION cGMP Smooth muscle cell Endothelium

  20. Bronchiolitis Obliterans Syndrome [BOS] “Constrictive Bronchiolitis”

  21. BOS: Stanford Experience Prevalence of BOS > 3 months post-transplant ~ 64% Reinchenspurner H, et al. Ann Thorac Surg 1996; 62: 1467

  22. Non-risk Factors Pre-LT CMV status, gender, donor age High panel reactive antibody (PRA). Bronchiolitis Obliterans Syndrome Risk Factors • Acute rejxn: RR=1.25* • CMV: RR=1.12* • Recipient age: RR=1.009/yr* • Antibody induction: RR=0.84 • Single lung: RR=1.24 • Incompatible lymphocyte Xmatch: RR=1.68 *p<0.01 Novartis Lung Transplant Database, 1998

  23. U.C.L.A. Immunosuppressive Protocol • Tacrolimus (Prograf) • Mycophenolate mofetil (Cellcept) • Prednisone • rATG (Thymoglobulin ) x 1-3 days • BOS  Methotrexate Sirolimus  rATG

  24. Cellcept [MMF] versus Imuran  [AZA] after Lung Transplantation XSD [95%C.I. For difference: 0.13 to 0.82; p<0.01] Ross DJ, et al. J Heart Lung Transplant 1998; 17:768-74

  25. Collaborative Research U.C.L.A. Lung & Heart-Lung Transplant Program

  26. Role for C-C Chemokine MCP-1/CCR2 in BOS • Chemoattractant for mononuclear phagocytes, CD45RO+ T lymphocytes, B cells, & NK cells. • Involved in chronic inflammatory & fibroproliferative diseases e.g. rheumatoid arthritis. • MCP-1 binds & signals through seven-transmembrane G protein-coupled receptor, CCR2. Belperio JA, et al. J Clin Invest 2001; 108:547-56.

  27. BALF MCP-1 in BOS • CCR2-/- knock-out murine model—  mononuclear recruitment after tracheal transplant & attenuation of BOS. P=0.01 P<0.0001 Belperio JA, et al. J Clin Invest 2001; 108:547-56.

  28. Human Defensins:Potential Effects on Adaptive Immunity • (a-HD)  Neutrophil chemotaxis through epithelial elaboration of IL-8. • (a-HD)  T-cell release of g-IFN, IL-6 & IL-10 • (HbD-2)  Memory helper T-lymphocytes (CD4+/CD45RO+) & progenitor-derived immature dentritic cells (CD34+) through chemokine receptor (CCR6).1 1. Yang D, et al. Science 2000; 286(5439):525

  29. BAL [HBD2]   p=0.001; Kruskal-Wallis ANOVA (MedianSEM) • Ross DJ, et al. J Heart and Lung Transplant 2002; 21(1):A75.

  30. Lung Transplantation David J. Ross, M.D. Medical Director, Lung & Heart-Lung Transplant Program Director, Pulmonary Hypertension Program Associate Professor of Medicine U.C.L.A. School of Medicine dross@mednet.ucla.edu (310) 825-6068

More Related